A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) Lesions

Clinical trial NCT07275723 · COMPLETED

Trial details

NCT number: NCT07275723
Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions Excluding the Central Nervous System (CNS)

Start date: 2025-11-14
Primary completion: 2026-04-18
Enrollment: 309

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.